Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study.

ABSTRACT:

Introduction

The study aimed to determine the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in the treatment of polymyalgia rheumatica (PMR) complicated by rheumatoid arthritis (RA).

Methods

Patients with PMR which could be classified as RA and who were treated with bDMARDs were included in the analysis. The primary endpoint was the clinical Polymyalgia Rheumatica Activity Score (Clin-PMR-AS) after 26 weeks of treatment, and the secondary endpoint was adverse events during the observation period.

Results

A total of 203 patients with PMR which was resistant or intolerant to glucocorticoids and could be classified as RA were receiving bDMARDs and were enrolled in the study. There were 83, 82, and 38 patients in the tumor necrosis fact

SUBMITTER: Ohkubo N 

PROVIDER: S-EPMC11422537 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature